AstraZeneca (AZN) is initiating coverage with a 'Strong Buy' rating, bolstered by a robust 8% revenue growth in Q1 2026. The company's performance was particularly driven by its Oncology and Rare Disease segments, which reported impressive growth rates of 16% and 15%, respectively. This growth was largely attributed to the successful sales of its key products, IMFINZI and ULTOMIRIS. Furthermore, AstraZeneca announced positive phase 3 trial results for IMFINZI, targeting unresectable hepatocellular carcinoma (HCC), and ULTOMIRIS, aimed at treating IgA nephropathy (IgAN). These results unlock significant expansion opportunities for the company. In addition to surpassing Q1 revenue estimates, AstraZeneca reaffirmed its guidance for 2026, anticipating mid-to-high single-digit revenue growth and low double-digit earnings per share growth. The company's strong portfolio and successful clinical trials position it well for future growth, making it an attractive investment option for those looking to capitalize on the biotech sector.